A5040466212- Platelet Disorders and Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Cytokine Signaling Pathways and Interactions
- Immune Cell Function and Interaction
- Cell Adhesion Molecules Research
- Melanoma and MAPK Pathways
- interferon and immune responses
- melanin and skin pigmentation
- Immunotherapy and Immune Responses
- NF-κB Signaling Pathways
- PI3K/AKT/mTOR signaling in cancer
- Neuroscience and Neuropharmacology Research
- TGF-β signaling in diseases
- Acute Myeloid Leukemia Research
- Carcinogens and Genotoxicity Assessment
- Lipid metabolism and disorders
- Hepatitis C virus research
- Pancreatic function and diabetes
- Plant nutrient uptake and metabolism
- Complement system in diseases
- Radioactive contamination and transfer
- Hematopoietic Stem Cell Transplantation
- HER2/EGFR in Cancer Research
- Kruppel-like factors research
Rutgers, The State University of New Jersey
2005-2022
Rutgers Cancer Institute of New Jersey
2010-2018
Cancer Institute of Florida
2010
Johnson University
2010
Inserm
1995-2002
Institut Gustave Roussy
1996-2002
Centre National de la Recherche Scientifique
1998-1999
Hôpital Cochin
1997
Innothera (France)
1995
Bicêtre Hospital
1993
In this study, we have characterized the early steps of hematopoiesis during embryonic stem cell differentiation. The immunophenotype hematopoietic progenitor cells derived from murine was determined using a panel monoclonal antibodies specific for differentiation antigens. Surprisingly, CD41 antigen (αIIb integrin, platelet GPIIb), essentially considered to be restricted megakaryocytes, found on large proportion within embryoid bodies although very few megakaryocytes were detected....
225 Background: Novel targeted therapies entered the treatment landscape in patients with HER2-positive metastatic colorectal cancer (mCRC). To ensure that these are used effectively, clinicians must assess tumor HER2 status and recognize how HER2-directed modalities fit into current paradigm. further enable to integrate HER2-targeted therapies, an educational program was designed 2023. Methods: A one-hour online, video-based for their teams hosted on MedLive from February 2023 one year....
Background Clinical and epidemiological observations regarding varicose veins, such as their predominance in women the occurrence of venous stasis during sex-hormone therapy, luteal phase menstrual cycle, pregnancy, suggest a sex hormone–dependency this pathology. In present study, analysis steroid receptors was used to determine if these effects were due direct hormonal action on saphenous vein. Methods Results Biopsy samples obtained from patients undergoing stripping removal veins....
// Ahmed Lasfar 1, 2 , Andrew de la Torre 3, 4 Walid Abushahba 5 Karine A. Cohen-Solal 2, 6 Ismael Castaneda 3 Yao Yuan 7 Kenneth Reuhl Zloza Elizabeth Raveche Debra L. Laskin Sergei V. Kotenko 1 Department of Pharmacology and Toxicology, Ernest Mario School Pharmacy, Rutgers, the State University New Jersey, Piscataway, NJ, USA Rutgers Cancer Institute Brunswick, Surgery, Jersey Medical School, The Newark, St Joseph's Center, Paterson, Microbiology, Biochemistry Molecular Genetics, Center...
// Rajeev K. Boregowda 1 , Daniel J. Medina Elke Markert 2 Michael A. Bryan Wenjin Chen 3, 4 Suzie 5 Anna Rabkin Vido 6 Samuel I. Gunderson 7 Marina Chekmareva David Foran Ahmed Lasfar 8, 9 James S. Goydos 10 Karine Cohen-Solal 11 Division of Medical Oncology, Department Medicine, Robert Wood Johnson School, Rutgers Cancer Institute New Jersey, Rutgers, The State University Brunswick, NJ 08903, USA Research UK Beatson Institute, Glasgow, G61 1BD Scotland, 3 Center for Biomedical Imaging &...
Melanoma cells are resistant to transforming growth factor-β (TGFβ)-induced cell-cycle arrest. In this study, we investigated a mechanism of resistance involving regulatory domain, called linker region, in Smad2 and Smad3, main downstream effectors TGFβ. culture tumor samples exhibited constitutive Smad3 phosphorylation. Treatment melanoma with the MEK1/2 inhibitor, U0126, or two pan-CDK GSK3 inhibitors, Flavopiridol R547, resulted decreased phosphorylation Smad3. Overexpression...
Riluzole, an inhibitor of glutamate release, has shown the ability to inhibit melanoma cell xenograft growth. A phase 0 clinical trial riluzole as a single agent in patients with resulted involution tumors associated inhibition both mitogen-activated protein kinase (MAPK) and phophoinositide-3-kinase/AKT (PI3K/AKT) pathways 34% patients. In present study, we demonstrate that inhibits AKT-mediated glycogen synthase 3 (GSK3) phosphorylation lines. Because have demonstrated GSK3 is involved two...